Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ● Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational

Event · Earnings
Original reporting
Published Aug 6, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RLMD
Bullish
medium confidence
Mentioned
$RLMD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RLMDBullishMed
01

Why it matters

The disclosure combines (1) a cash runway update, (2) specific planned regulatory milestones for both programs, and (3) a leadership change, which together can shift perceived probability-weighted timelines and near-term risk for RLMD.

02

Market read

Traders can update RLMD’s risk model around FDA/IND timing, manufacturing/CMC execution, and cash runway through 2029 based on the Q2 8-K details.

03

What to watch

R&D expense rose sharply in Q2 due to higher NDV-01 and sepranolone study and manufacturing/storage costs, which may pressure valuation even with a longer cash runway.

Relevance 7/10Novelty 7/10Timing: today’s 4:30 PM ET conference call and webcast; focus on year-end 2026 IND timing

Background

Relmada is a clinical-stage biotech advancing NDV-01 (sustained-release intravesical gemcitabine/docetaxel) and sepranolone, and this 8-K provides Q2 financials plus execution milestones toward IND filings.

Company-level read

Ticker impact

$RLMDBullishMedium confidence
Context

Relmada reports Q2 results and updates that it expects NDV-01 and sepranolone IND filings by year-end 2026, with Phase 3 RESCUE initiation after IND clearance.

Expected impact

Moderate upside bias into the next IND-related milestones, with volatility around FDA alignment and manufacturing/CMC progress.

Evidence & confidence

The filing is a primary disclosure (8-K with exhibit) including cash balance, expense drivers, and specific planned regulatory/clinical timing, which can re-rate biotech risk and runway expectations.

Market effects

Biotech investors may re-focus on clinical-stage intravesical oncology and CNS programs where CMC progress and IND timing reduce perceived regulatory risk.

Primarily US small-cap biotech sentiment via Russell index additions effective June 26, 2026.

Limited direct global spillover; could marginally affect sentiment for similar development-stage oncology/CNS drugmakers.

Counterpoint

Year-end IND timing is still conditional on FDA clearance; any CMC or formulation issues could push milestones and increase burn.

Key entities

  • Relmada Therapeutics, Inc.

    Clinical-stage biotech advancing NDV-01 and sepranolone; filed an 8-K with Q2 results and business update.

  • NDV-01

    Sustained-release intravesical formulation of gemcitabine and docetaxel for NMIBC; planned US IND by year-end 2026 and Phase 3 RESCUE initiation after IND clearance.

  • sepranolone

    Program with formulation development complete; planned US IND by year-end 2026 and Phase 2 proof-of-concept initiation in Prader-Willi Syndrome after IND clearance.

  • Bipin Dalmia

    Appointed Chief Business Officer during the quarter.

Related articles

$RLMDMedAI 8/10

Relmada (RLMD) Q3 2026 Earnings Call Transcript

Relmada (RLMD) reported Q3 2026 progress, including IND submissions for NDV-01 and sepranolone by year-end. NDV-01 showed 86% 18-month CR rate in NMIBC, with favorable safety. Phase 3 trials planned. Cash position of $202.1M expected to fund operations through 2029. Net loss was $13.9M, up from $10.1M YoY.

$RLMDHigh

Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND

$RLMDMed

Relmada (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics (RLMD) reported Q2 2026 results and an execution update. Cash was $217.7M at June 30, 2026, funding operations through 2029. Net loss was $12.9M ($0.11/share). Management expects IND filings for NDV-01 and sepranolone by end-2026 and Phase 3 RESCUE enrollment to start after IND clearance.

$WMTHighAI 8/10

Walmart Has Raised Its Dividend 53 Straight Years. I'd Buy It Before December and Never Sell.

Walmart (WMT) reported better-than-expected sales and profits, raised its full-year forecast, and announced 53 consecutive years of dividend increases. Despite this, its stock fell 2% in early trading. The company's omnichannel model, advertising business, and AI shopping assistant contributed to its growth, while rising diesel prices and slowing same-store sales growth pose challenges. Walmart's dividend is payable to shareholders of record on December 11.